We use privacy-friendly analytics. Read our privacy policy.

Compound Profile

Bupropion

Compound profile with evidence, safety, and practical fit.

Safety context — U. Details

Profile-wide ·C Limited
Bupropion monograph visual
Generated profile category visual

At a glance

From this profile's structured data
Evidence
Grade C
Safety
U.
Profile context
norepinephrine and dopamine reuptake inhibition, monoamine signaling
Next steps

Continue reading

Quick stats

Evidence level
Limited evidence
Typical onset
Varies by prep
Safety rating
Safety context: Use caution
Best for
Norepinephrine And Dopamine Reuptake Inhibition, Monoamine Signaling

Safety

Safety & Cautions

U. S.

High caution

Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.

  • Interaction-AwareMedication or interaction context is explicitly noted.

Evidence Summary

Profile-wide ·C Limited

Evidence lens

Read as directional context, not settled clinical proof.

LimitedLimited evidence

Human clinical evidence: Present in source signals

Mechanistic / preclinical: Mechanism mapped

Research maturity: Emerging research — main contexts: Norepinephrine And Dopamine Reuptake Inhibition · Monoamine Signaling

Safety boundary: Safety note available — U.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Limited evidence

Bupropion has a limited evidence rating.

General wellnessGeneral wellness
Citation density
2.0
Sources
4
Effects
2
Research recency
Mixed recency
Evidence Grade

Grade C: Limited Evidence

Evaluation of methodological rigor, population reach, and evidence alignment.

Design Match
Meta analysis
Risk of Bias
Low
Consistency
Consistent
Strongest recorded design is a meta analysis, drawn from 3 recorded studies, 3 in people. No disagreement is recorded across them.
How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
Clinical Study Summaries (4)3 human evidence sources · 1 human trial · Participant totals not consistently reported · Consistency not yet classifiable

Filter by study class

Showing 4 of 4 studies.

What the evidence actually shows

This table contains 4 structured sources, including 3 human evidence sources; 1 is a human trial.

StudyDesignNDoseDurationPopulationOutcomeResult & magnitudeSource

A 2018 network meta-analysis of 522 randomized trials involving 116,477 adults found all 21 included antidepressants more efficacious than placebo for acute major depressive disorder; bupropion was among the included treatments, with comparative efficacy and acceptability varying across head-to-head comparisons and evidence certainty ranging from moderate to very low.

Background
Meta-analysis

Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies.

—————A 2018 network meta-analysis of 522 randomized trials involving 116,477 adults found all 21 included antidepressants more efficacious than placebo for acute major depressive disorder; bupropion was among the included treatments, with comparative efficacy and acceptability varying across head-to-head comparisons and evidence certainty ranging from moderate to very low.PubMed →

A 2016 systematic review and meta-analysis of 51 studies found placebo-controlled evidence supporting bupropion's antidepressant efficacy, while many head-to-head comparisons found broadly similar depression outcomes to other antidepressants and study heterogeneity limited strong comparative conclusions.

Background
Meta-analysis

Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies.

—————A 2016 systematic review and meta-analysis of 51 studies found placebo-controlled evidence supporting bupropion's antidepressant efficacy, while many head-to-head comparisons found broadly similar depression outcomes to other antidepressants and study heterogeneity limited strong comparative conclusions.PubMed →

Two randomized double-blind placebo-controlled studies comparing bupropion XL with escitalopram found treatment-emergent sexual dysfunction was less frequent with bupropion XL than with escitalopram among participants with normal sexual functioning at baseline.

Background
Randomized controlled trial

Randomly assigns participants to interventions or controls, reducing many sources of bias when the trial is conducted well.

—————Two randomized double-blind placebo-controlled studies comparing bupropion XL with escitalopram found treatment-emergent sexual dysfunction was less frequent with bupropion XL than with escitalopram among participants with normal sexual functioning at baseline.PubMed →

A 2026 U.S. DailyMed label for bupropion hydrochloride extended-release tablets (XL) identifies the product as an aminoketone antidepressant indicated for major depressive disorder and prevention of seasonal major depressive episodes in seasonal affective disorder, and carries a boxed warning regarding suicidal thoughts and behaviors in pediatric and young adult patients.

Background
Other / unclear

The study design is not yet classified clearly enough to infer its place in the evidence hierarchy.

—————A 2026 U.S. DailyMed label for bupropion hydrochloride extended-release tablets (XL) identifies the product as an aminoketone antidepressant indicated for major depressive disorder and prevention of seasonal major depressive episodes in seasonal affective disorder, and carries a boxed warning regarding suicidal thoughts and behaviors in pediatric and young adult patients.Source →

Dosing

No standardized dose
No standardized dose is established for this ingredient in our source data. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Review available sources for Bupropion

Independent database mapping — evaluated separately from safety and efficacy scores.

Check sourcing options

Affiliate disclosure: Shopping links may earn this site a commission at no cost to you. Links are chosen on quality and availability, never commission tiers; safety warnings and evidence ratings stay independent.

Free safety checklist

Get the Bupropion evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?